Journal of Cancer Prevention 2015; 20(3): 185-192
Published online September 30, 2015
© Korean Society of Cancer Prevention
Bu Young Choi1, and Bong-Woo Kim2
1Department of Pharmaceutical Science and Engineering, Seowon University, Cheongju, Korea, 2Department of Cosmetic Science and Technology, Seowon University, Cheongju, Korea
Correspondence to :
Bong-Woo Kim, Department of Cosmetic Science and Technology, Seowon University, 377-3 Musimseo-ro, Seowon-gu, Cheongju 28674, Korea, Tel: +82-43-299-8493, Fax: +82-43-299-8470, E-mail: firstname.lastname@example.org, ORCID: Bong-Woo Kim, http://orcid.org/0000-0001-8767-9519
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
We investigated the anti-cancer effects of withaferin-A on the proliferation and migration of human colorectal cancer (HCT116) cells. And we evaluated the effects of withaferin-A on the transcriptional activity of STAT3 and the growth of HCT116 cells in xenograft mouse tumor model. In the present study, we found that withaferin-A inhibited the proliferation and migration of HCT116 cells in a concentration-dependent manner. Treatment of HCT116 cells with withaferin-A attenuated interleukin-6-induced activation of STAT3, which has been implicated in the development and progression of colon cancer. To examine the effect of withaferin-A on HCT116 cells proliferation in vivo, we generated HCT116 cells xenograft tumors in Balb/c nude mice and treated the tumor bearing mice with or without withaferin-A intraperitoneally. Treatment with withaferin-A exhibited significant decrease in the volume and weight of tumors as compared to untreated controls. The present study suggests that withaferin-A holds the potential to be developed as a small molecule inhibitor of STAT3 for the treatment of HCT116.
We investigated the anti-cancer effects of withaferin-A on the proliferation and migration of human colorectal cancer (HCT116) cells. And we evaluated the effects of withaferin-A on the transcriptional activity of STAT3 and the growth of HCT116 cells in xenograft mouse tumor model.
In the present study, we found that withaferin-A inhibited the proliferation and migration of HCT116 cells in a concentration-dependent manner. Treatment of HCT116 cells with withaferin-A attenuated interleukin-6-induced activation of STAT3, which has been implicated in the development and progression of colon cancer. To examine the effect of withaferin-A on HCT116 cells proliferation in vivo, we generated HCT116 cells xenograft tumors in Balb/c nude mice and treated the tumor bearing mice with or without withaferin-A intraperitoneally. Treatment with withaferin-A exhibited significant decrease in the volume and weight of tumors as compared to untreated controls.
The present study suggests that withaferin-A holds the potential to be developed as a small molecule inhibitor of STAT3 for the treatment of HCT116.
Keywords: Withaferin-A, Colorectal neoplasms, STAT3 transcription factor, Heterografts
Colorectal cancer (CRC) is one of the most common cancers in the world.1 According to global cancer statistics, CRC appears as the fourth leading cause of cancer-related deaths worldwide.2 Although remarkable progress has been made in developing effective chemotherapeutic agents to treat early-stage CRC, emerging incidences of drug resistance often leads to chemotherapy failure, and impose high toxicity to bone marrow, gastrointestinal tract, and skin.3 Therefore, there is an increasing interest in searching for new treatment and/or prevention modalities for CRC.
In recent years, bioactive plant constituents have got much attention for the development of new therapeutic agents. A wide variety of phytochemicals are being screened for their anticancer potential. Withaferin-A (Fig. 1A), originally isolated from
Tumor promotion and progression involve inappropriately increased cell proliferation, evasion from apoptosis, induction of tumor angiogenesis, and increased migration, invasion and metastasis of cancer cells. Among various oncogenic signaling pathways, STAT3 plays a crucial role in CRC.16 It has been reported that persistent STAT3 activation enhances the proliferation of colon cancer cells in culture and the growth xenograft tumors of these cells when implanted in nude mice.17 Moreover, the blockade of STAT3 signaling led colon cancer cells to undergo apoptosis.18 Since abnormal activation of STAT3 signaling induces transcriptional activation the genes encoding various proteins involved in apoptosis, cell cycle progression, angiogenesis, invasion and metastasis, targeted inhibition of STAT3 signaling is a pragmatic approach in preventing CRC.19,20 Therefore, many studies are investigated to develop new therapeutic agents that are able to directly inhibit the activation of STAT3 signaling.21,22 In this study, we have investigated the effects of withaferin-A on the proliferation and migration of human colorectal cancer (HCT116) cells and the growth of these cell’s xenograft tumors in nude mice. Here, we report that withaferin-A inhibited the proliferation, migration and xenograft tumor growth of HCT116 cells by suppressing the STAT3 transcriptional activity in HCT116 cells.
Withaferin-A was purchased from Sigma Aldrich (St. Louis, MO, USA). Withaferin-A was dissolved in methanol at a stock concentration of 10 mM and diluted with medium prior to experimental procedures (final concentration of methanol ≤ 0.01%). Methylthiazolyldiphenyl-tetrazolium bromide (MTT) and paraformaldehyde was purchased from Sigma Aldrich. Primary antibody for interleukin-6 (IL-6) was from R&D Systems (Minneapolis, MN, USA) and that of proliferating cell nuclear antigen (PCNA) and secondary antibodies were from Cell signaling Technology (Beverly, MA, USA).
HCT116 cells (ATCC, Rockville, MD, USA) were grown in the RPMI-1640 medium (Gibco?; Life Technologies, Grand Island, NY, USA) supplemented with 10% FBS, 100 U/mL penicillin and streptomycin. Cells were maintained in an incubator at 37°C in 5% CO2. For the treatment of cells with withaferin-A, cells were cultured in RPMI-1640 medium without FBS for 12 hours.
Cells were plated at a density of 1 × 104 cells per well into 96-well plates and maintained at 37°C for 24 hours. Cells were treated with various concentrations of withaferin-A for 12 hours. Fresh medium containing 50 μL of MTT solution (0.5 mg/mL) was then added to each well. After incubation for another 3 hours, the MTT formazan crystals were dissolved in dimethyl sulfoxide (DMSO) and viable cells were detected by measuring the absorbance at 570 nm using a microplate reader (Molecular Devices, Sunnyvale, CA, USA).
For a scratch wound healing assay, HCT116 cells were sub-cultured in 12-well plates and grown to 70% to 80% confluence. Monolayer of cells was scratched with a sterile 10-μL micropipette tip across center of the well. Cells were washed 3 times with PBS to remove cellular debris, and were exposed to medium containing withaferin-A. Cell migration was observed under a bright-field microscope (Olympus, Tokyo, Japan) at a magnification of 100×. The migration velocity was calculated independently in five randomly chosen fields of 6 scratches, and the percentage of inhibition was shown using control cells at 100%.
STAT3 luciferase-reporter gene assay was performed as described previously.23 Briefly, STAT3-luc constructs were stably transfected into HCT116 cells. Cells were plated at a density of 2 × 104 cells per well in 96-well plate in RPMI medium and treated with IL-6, withaferin-A or methanol (control). After incubation for another 12 hours, cells were lysed by passive lysis buffer and incubated for 15 minutes in orbital shaker. The luciferase activity was measured by dual-luciferase reporter assay kit (Promega, Madison, WI, USA) according to the manufacturer’s protocol.
HCT116 cells were fixed with 3.7% paraformaldehyde for 10 minutes and then permeabilized with 0.1% Triton X-100 (Sigma Aldrich). The cells were blocked for 1 hour with blocking buffer (5% bovine serum albumin in PBS). The subsequent incubations with primary antibodies and fluorescent-conjugated secondary antibodies were conducted at room temperature. Immunofluorescence images were captured by a laser scanning confocal microscope (ZEISS LSM 510 META; Carl Zeiss, Oberkoden, Germany).
HCT116 cells (6 × 106 cells/200 μL) were subcutaneously injected into the flank of the female athymic BALB/c nude mice at the age of 6 weeks. Seven days after the injection of cells, mice were randomized into treatment groups and control groups. The treatment groups were injected with withaferin-A (2 mg/kg of body weight, DMSO 0.1% v/v) every 2 days and the control groups were injected with vehicle (DMSO 0.1% v/v), intraperitoneally. Tumor diameters were measured 3 times a week, and tumor volumes were calculated according to the following formula (length × width2 × π/6). After 32 days of treatment, the mice were sacrificed and the tumors were harvested, weighted, and fixed in fix solution (4% paraformaldehyde) for immunohistochemistry.
Statistical analysis was performed by either two-tailed Student’s
To investigate whether withaferin-A inhibits the proliferation and growth of HCT116 cells in culture, cells were treated with varying concentrations of withaferin-A for indicated periods and the levels of proliferation were measured. As shown in Figure 1, the MTT assay and cell counting revealed that withaferin-A significantly decreased the viability of HCT116 cells in concentration- and time-dependent manner. Cell viability was significantly decreased by treatment with withaferin-A at concentrations below 5 μM, showing 69% reduction in the proliferation of HCT116 cells after 12 hour (Fig. 1B). To assess the effect of withaferin-A on the proliferation of HCT116 cells, we counted the cell at 2, 4, 6, and 8 days after treatment with 1 μM withaferin-A. At the last day of treatment, the cells showed a dramatic decrease in cell proliferation when compared with the vehicle group (Fig. 1C).
Since tumor cell migration is a critical step in the invasion and metastasis of cancer, we examined the effect of withaferin-A on the migration ability of HCT116 cells. Confluent cells were scraped across center of the well and the remaining cells were incubated to migrate into the gap in the absence or presence of withaferin-A (Fig. 2A). After 24 hours incubation, the wound gap was wider in the withaferin-A-treated groups (0.001?1 μM) as compared to the untreated group, indicating that withaferin-A inhibits the motility of HCT116 cells (Fig. 2A and 2B). Next, we tested the effects of withaferin-A on cell migration by the Transwell chamber assay. As shown in Figure 2C, treatment with withaferin-A (1 μM) significantly reduced cell migration measured as percent of control (Fig. 2D).
Since inappropriate induction of a variety of STAT3 target genes has been implicated in the development of CRC, we assessed the effects of withaferin-A on the transcriptional activity of STAT3. HCT116 cells were stably transfected with STAT3-luc constructs, and incubated with various concentrations (0.0625, 0.125, 0.5, or 1 μM) of withaferin-A. As shown in Figure 3, incubation of cells with IL-6 induced the STAT3 reporter gene activity, which was blunted by treatment of cells with withaferin-A in a concentration-dependent manner. And, we assessed whether withaferin-A treatment induces nuclear translocation of STAT3. Immunofluorescence staining showed that IL-6-induced nuclear distribution of STAT3 in HCT116 cells significantly reduced by after treatment with 1 μM withaferin-A.
We next evaluated the effect of withaferin-A on the growth of HCT116 cells in vivo by using a xenograft mouse tumor model. Athymic BALB/c nude mice were subcutaneously injected with HCT116 cells to generate xenograft tumors. Intraperitoneal administration of withaferin-A every 2 days for 32 days led to a significant decrease in the volume and weight of tumors as compared to untreated controls without affecting the mean body weight (Fig. 4). The mean tumor volume of withaferin-A-treated mice was 404.5 ± 67.6 mm3, which was approximately 1.44 fold lower compared with that in control mice (582.6 ± 42.6 mm3,
Plant secondary metabolites always remain in the front line in the development of new therapeutic agents. In the context of emerging evidence of chemotherapy failure and growing trend of chemo-resistance, bioactive phytochemicals are given much importance for searching new anticancer therapeutics. Numerous preclinical studies have demonstrated the anticancer effects of a wide variety of plant polyphenols. Withaferin-A has been extensively investigated for its diverse pharmacological activities.24 Although the anticancer effects of withaferin-A has been reported in various preclinical studies,15,25,26 its molecular mechanism of action remains elusive. Our study has revealed that withaferin-A decreased the viability of HCT116 cells in a time- and concentration- dependent manner. It has also been reported earlier that withaferin-A induces apoptosis in various colon cancer cells including HCT116 cells by blocking Notch1-mediated prosurvival signaling pathways.27 However, withaferin-A had no effect of cell viabilities in androgen sensitive normal human fibroblasts and prostate adenocarcinoma cells indicating that withaferin-A induces selective tumor death.28 Our study also revealed that withaferin-A inhibited the proliferation of HCT116 cells.
Previous studies have demonstrated that withaferin-A induces apoptosis in various cancer cells by multiple mechanisms including the generation of ROS, mitochondrial dysfunction, cell cycle arrest, inactivation of prosurvival signaling molecules, such as extracellular signal-regulated kinase, c-Jun N terminal kinase, NF-κB and STAT3.6,11,13,29 These prosurvival factors are also involved in the enhanced migration of cancer cells. Our findings that withaferin-A inhibited migration of HCT116 cells suggests that the compound might interfere with the cell signaling pathways those are involved in increased proliferation and migration of cancer cells.
One of the major oncogenic signaling pathways is the STAT3 signaling. The inappropriate activation of STAT3 contributes to the survival, proliferation, chemo-resistance, and metastasis of cancer cell, and is constitutively overexpressed in various cancer cells such as sarcoma, lymphoma, carcinoma and leukemia.30 It has been reported that STAT3 activation increased the rate of proliferation and growth of colon cancer cells,17 while inactivation of these gene induces apoptosis.18 Therefore, many small molecules have been discovered to directly inhibit STAT3 activation. Although several small molecules such as alantoactone, resveratrol and fluacrypyrim inhibit STAT3 signaling, most of these molecules block the STAT3 signaling by suppress STAT3 upstream kinases indirectly.21?23 However, withaferin-A was reported to cause direct inhibition of STAT3 and induction of apoptotic cell death in various cancer cells.13,31,32
The activation of STAT3 is mediated through the phosphorylation of its tyrosine-705 residue followed by the formation of STAT3 dimer,33 which then translocates to the nucleus and binds to the gamma activated sites of genes encoding proteins engaged in increased cell proliferation and migration. These genes products include cell cycle regulatory proteins (e.g., cyclins and cyclin-dependent kinases), antiapoptotic proteins (e.g., Bcl-2, Bcl-xl), and cell proliferation markers (e.g., PCNA and survivin).34 The phosphorylation of STAT3 at tyrosine-705 residue is mediated by the upstream kinases, such as JAK2.35 In a recent study, Yco et al.15 demonstrated that withaferin-A inhibited STAT3 phosphorylation, thereby blocked STAT3 dimerization by directly binding to the STAT3 Src homology (SH2). Our findings that withaferin-A attenuated the transcriptional activity of STAT3 in IL-6 stimulated HCT116 cells were in good correlation with the report of Um et al.,13 who demonstrated that withaferin-A diminished IL-6-induced phosphorylation of JAK2 and STAT3 in renal carcinoma cells. Further in vivo experimental evidence of decreased xenograft tumor growth of HCT116 cells and the reduced expression of PCNA in tumor tissues upon administration of withaferin-A suggest the potential of this compound to be used for the prevention and/or therapy of cancer. In conclusion, withaferin-A is able to inhibit not only the proliferation of HCT116 cells but also attenuated the tumor growth in vivo by suppressing STAT3 signaling pathways.
Hyuntak Na, Jeeyoo Lee, Sooyoung Cho, Woo-Kyoung Shin, Ji-Yeob Choi, Daehee Kang, Aesun ShinJ Cancer Prev 2022; 27(4): 229-238 https://doi.org/10.15430/JCP.2022.27.4.229
Nur Mahirah Amani Binti Mohammad, Mohd Razif Shahril, Suzana Shahar, Michael Fenech, Razinah SharifJ Cancer Prev 2022; 27(4): 208-220 https://doi.org/10.15430/JCP.2022.27.4.208
Soo-Young Na, Ki Bae Kim, Yun Jeong Lim, Hyun Joo SongJ Cancer Prev 2022; 27(3): 147-156 https://doi.org/10.15430/JCP.2022.27.3.147